Diffusion-weighted MRI as a biomarker of tumor radiation treatment response heterogeneity: A comparative study of whole-volume histogram analysis versus voxel-based functional diffusion map analysis

Translational Oncology

Volumn 6, Issue 5, 2013, Pages 554-561

  Lemasson, Benjamin ^a   Galbán, Craig J ^a   Boes, Jennifer L ^a   Li, Yinghua ^a   Zhu, Yuan ^a   Heist, Kevin A ^a   Johnson, Timothy D ^b   Chenevert, Thomas L ^a   Galbán, Stefanie ^b   Rehemtulla, Alnawaz ^b   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CELL HETEROGENEITY; CELL PROLIFERATION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; HISTOGRAM; HUMAN; HUMAN CELL; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVERALL SURVIVAL; RADIATION DOSE ESCALATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VOXEL BASED MORPHOMETRY;

EID: 84885822726     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13532     Document Type: Article

References (31)

1. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, et al. (2008). Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113, 1953-1968.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459-466.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
4. Jansen M, Yip S, and Louis DN (2010). Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9, 717-726.
5. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, et al. (2010). Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 28, 1963-1972.
6. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M, and Stupp R (2011). Current concepts and management of glioblastoma. Ann Neurol 70, 9-21.
7. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, Johnson TD, Junck L, Robertson PL, Muraszko KM, et al. (2003). Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2, 581-587.
8. Cha S (2009). Neuroimaging in neuro-oncology. Neurotherapeutics 6, 465-477.
9. Lemasson B, Christen T, Tizon X, Farion R, Fondraz N, Provent P, Segebarth C, Barbier EL, Genne P, Duchamp O, et al. (2011). Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. NMR Biomed 24, 473-482.
10. Barajas RF, Rubenstein JL, Chang JS, Hwang J, and Cha S (2010). Diffusionweighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31, 60-66.
11. Hall DE, Moffat BA, Stojanovska J, Johnson TD, Li Z, Hamstra DA, Rehemtulla A, Chenevert TL, Carter J, Pietronigro D, et al. (2004). Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res 10, 7852-7859.
12. Galbán S, Lemasson B, Williams TM, Li F, Heist KA, Johnson TD, Leopold JS, Chenevert TL, Lawrence TS, Rehemtulla A, et al. (2012). DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma. PLoS One 7, e35857.
13. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-2036.
14. Moffat BA, Chenevert TL, Lawrence TS, Meyer CR, Johnson TD, Dong Q, Tsien C, Mukherji S, Quint DJ, Gebarski SS, et al. (2005). Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci USA 102, 5524-5529.
15. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, and Ross BD (2006). The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 8, 259-267.
16. Hamstra DA, Chenevert TL, Moffat BA, Johnson TD, Meyer CR, Mukherji SK, Quint DJ, Gebarski SS, Fan X, Tsien CI, et al. (2005). Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci USA 102, 16759-16764.
17. Tchougounova E, Kastemar M, Bråsäter D, Holland EC, Westermark B, and Uhrbom L (2007). Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 26, 6289-6296.
18. Pitter KL, Galbán CJ, Galbán S, Saeed-Tehrani O, Li F, Charles N, Bradbury MS, Becher OJ, Chenevert TL, Rehemtulla A, et al. (2011). Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 6, e14545.
19. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, and Schmainda KM (2010). Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31, 538-548.
20. Meyer CR, Boes JL, Kim B, Bland PH, Zasadny KR, Kison PV, Koral K, Frey KA, and Wahl RL (1997). Demonstration of accuracy and clinical versatility of mutual information for automatic multimodality image fusion using affine and thin-plate spline warped geometric deformations. Med Image Anal 1, 195-206.
21. Galbán CJ, Chenevert TL, Meyer CR, Tsien C, Lawrence TS, Hamstra DA, Junck L, Sundgren PC, Johnson TD, Ross DJ, et al. (2009). The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15, 572-576.
22. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, et al. (2012). Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progressionfree and overall survival in newly diagnosed glioblastoma. Neuro Oncol 14, 333-343.
23. Hamstra DA, Galbán CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, Lawrence TS, Junck L, Ross DJ, Rehemtulla A, et al. (2008). Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26, 3387-3394.
24. Chung C, Jalali S, Foltz W, Burrell K, Wildgoose P, Lindsay P, Graves C, Camphausen K, Milosevic M, Jaffray D, et al. (2013). Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy. Int J Radiat Oncol Biol Phys 85, 805-812.
25. Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3, 1457-1466.
26. Rehemtulla A (2012). Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia 14, 1278-1289.
27. Lee KC, Hall DE, Hoff BA, Moffat BA, Sharma S, Chenevert TL, Meyer CR, Leopold WR, Johnson TD, Mazurchuk RV, et al. (2006). Dynamic imaging of emerging resistance during cancer therapy. Cancer Res 66, 4687-4692.
28. Reischauer C, Froehlich JM, Koh DM, Graf N, Padevit C, John H, Binkert CA, Boesiger P, and Gutzeit A (2010). Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 257, 523-531.
29. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, et al. (2007). A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia 9, 1003-1011.
30. Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D, Halliday J, Waterton JC, Gore JC, and Yankeelov TE (2012). Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology. Neoplasia 14, 54-64.
31. Lee KC, Sud S, Meyer CR, Moffat BA, Chenevert TL, Rehemtulla A, Pienta KJ, and Ross BD (2007). An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res 67, 3524-3528.